Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy

Transfusion and Apheresis Science

Volumn 49, Issue 2, 2013, Pages 185-188

  Schell, Amy M ^a   Petras, Melissa ^a   Szczepiorkowski, Zbigniew M ^a,b   Ornstein, Deborah L ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Corticosteroids; Heparin induced thrombocytopenia with thrombosis; Phlegmasia cerulea dolans; Rituximab; Therapeutic plasma exchange

Indexed keywords

ALBUMIN; ARGATROBAN; FRESH FROZEN PLASMA; HEPARIN; LEPIRUDIN; RITUXIMAB; VITAMIN K GROUP; WARFARIN;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; ANTIBODY PRODUCTION; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CASE REPORT; DNA POLYMORPHISM; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAINTNESS; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOCYTOPENIA WITH THROMBOSIS; HEPARINIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMB AMPUTATION; LUNG EMBOLISM; MECHANICAL THROMBECTOMY; PLASMAPHERESIS; REFRACTORY THROMBOCYTOPENIA; THROMBECTOMY; THROMBOCYTE COUNT; THROMBOSIS; VASCULAR PATENCY; VENOUS THROMBOEMBOLISM;

BELOW-KNEE AMPUTATIONS; BKA; CORTICOSTEROIDS; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOCYTOPENIA WITH THROMBOSIS; HIT; ODU; OPTICAL DENSITY UNITS; PHLEGMASIA CERULEA DOLANS; RITUXIMAB; THERAPEUTIC PLASMA EXCHANGE; TPE;

ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; MIDDLE AGED; PLASMA EXCHANGE; THROMBOCYTOPENIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84886639640     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.01.007     Document Type: Article

References (24)

1. Warkentin T.E. Heparin-induced thrombocytopenia. Hematol Oncol Clin N Am 2007, 21(4):589-607.
2. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):340S-380S.
3. Grouzi E., Kyriakou E., Panagou I., Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hem 2010, 16(6):663-667.
4. Warkentin T.E., Pai M., Sheppard J.I., et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30month, 16-patient case series. J Thromb Haemost 2011, 9(12):2389-2396.
5. Dierickx D., Delannoy A., Saja K., et al. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol 2011, 86(3):278-291.
6. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 344(17):1286-1292.
7. Lee D.H., Warkentin T.E., Denomme G.A., et al. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb Haemost 1998, 79(1):50-53.
8. Lindhoff-Last E., Wenning B., Stein M., et al. Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopenia. Clin Appl Thromb Hem 2002, 8(4):347-352.
9. Greinacher A., Holtfreter B., Krauel K., et al. Association of natural antiplatelet factor 4/heparin antibodies with periodontal disease. Blood 2011, 118(5):1395-1401.
10. Hursting M.J., Pai P.J., McCracken J.E., et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010, 134(5):774-780.
11. Welsby I.J., Um J., Milano C.A., Ortel T.L., Arepally G. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010, 110(1):30-35.
12. Jaben E.A., Torloni A.S., Pruthi R.K., Winters J.L. Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature. J Clin Apheresis 2011, 26(4):219-224.
13. Abdel-Razeq H.N., Bajouda A.A., Khalil M.M., Ashmeg A.K. Treating heparin-induced thrombocytopenia. The unconventional way. Saudi Med J 2004, 25(9):1258-1260.
14. Antonijevic N.M., Savic N.B., Perunicic J., et al. Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin. J Clin Apher 2006, 21(4):252-255.
15. Bouvier J.L., Lefevre P., Villain P., et al. Treatment of serious heparin-induced thrombocytopenia by plasma exchange: report on 4 cases. Thromb Res 1988, 51(3):335-336.
16. Brady J., Riccio J.A., Yumen O.H., Makary A.Z., Greenwood S.M. Plasmapheresis. A therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathol 1991, 96(3):394-397.
17. Manzano L., Yebra M., Vargas J.A., et al. Plasmapheresis in heparin-induced thrombocytopenia and thrombosis. Stroke 1990, 21(8):1236.
18. Nand S., Robinson J.A. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988, 28(3):204-206.
19. Poullin P., Pietri P.A., Lefevre P. Heparin-induced thrombocytopenia with thrombosis: successful treatment with plasma exchange. Br J Haematol 1998, 102(2):630-631.
20. Thorp D., Canty A., Whiting J., et al. Plasma exchange and heparin-induced thrombocytopenia. Prog Clin Biol Res 1990, 337:521-522.
21. Robinson J.A., Lewis B.E. Plasmapheresis in the management of heparin-induced thrombocytopenia. Semin Hematol 1999, 36(1 Suppl 1):29-32.
22. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for apheresis. J Clin Apheresis 2010, 25(3):83-177.
23. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
24. Lubenow N., Eichler P., Lietz T., Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005, 3(11):2428-2436.